Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study-Reference-Cited by-同舟云学术

Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study

Published:2021-09 Issue:9 Volume:35 Page:107972
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

DeRemer Christina E.,Vouri Scott M.,Guo Jingchuan,Donahoo William T.,Winterstein Almut G.,Shao Hui

Funder

Agency for Healthcare Research and Quality

National Institutes of Health

Patient-Centered Outcomes Research Institute

Centers for Disease Control and Prevention

University of Florida College of Pharmacy

Merck Sharp and Dohme

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Type 2 diabetes,2021

2. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017;Einarson;Cardiovasc Diabetol,2018

3. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?;Martín-Timón;World J Diabetes,2014

4. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Goff;J Am Coll Cardiol,2014

5. Projecting long-term diabetes complications through a BRAVO-based mock simulation for promoting diabetes prevention program (DPP);Shao;Diabetes,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes;Diabetes, Obesity and Metabolism;2024-05-23

2. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients;Metabolic Syndrome and Related Disorders;2024-04-01

3. How to Use Type 2 Diabetes Treatments in Clinical Practice;Textbook of Diabetes;2024-01-12

5. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis;Diabetes and Vascular Disease Research;2023-11